Low margins and competitive markets have prevented Takeda from establishing a moat.
Takeda slightly raised its underlying core earnings outlook for the full fiscal year following strong results for the first half of fiscal 2017, with underlying revenue growth of 6.7% and underlying core earnings growth of 44.4%. Sales in the U.S. drove growth (16.7%) while emerging markets showed weakness (3.4%) due to temporary China headwinds. Takeda’s key gastrointestinal drug Entyvio is gaining share and launching in new markets, and grew 43% to more than JPY 95 billion in the first half of...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.